Medical Use
Skyrizi is an interleukin-23 antagonist used to treat:
- -Moderate-to-severe plaque psoriasis (Ps) in adults eligible for systemic therapy or phototherapy.
- -Active psoriatic arthritis (PsA) in adults.
- -Moderately to severely active Crohn’s disease (CD) in adults.
Recommended Dosage:
- -Plaque Psoriasis and Psoriatic Arthritis: Administer 150 mg by subcutaneous injection at Week 0, Week 4, and then every 12 weeks. Skyrizi can be used alone or with non-biologic disease-modifying antirheumatic drugs (DMARDs).
- -Crohn’s Disease: For induction, administer 600 mg by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. For maintenance, administer 360 mg by subcutaneous injection at Week 12, and then every 8 weeks.
Before starting therapy with Risankizumab-rzaa injection, check liver enzymes and bilirubin levels. Avoid injecting into areas where the skin is tender, red, bruised, hardened, or affected by psoriasis. Only a healthcare professional or caregiver should administer the injection in the upper, outer arm.
If a dose is missed, administer it as soon as possible and then continue with the regular dosing schedule.
Warning & Precautions
- -Hypersensitivity: Do not use risankizumab-rzaa in patients with a known history of serious hypersensitivity reactions to the drug or its excipients.
- -Infection Risk: Skyrizi may increase the risk of infections. Do not start treatment in patients with any significant active infection until it is resolved or adequately treated. If an infection develops or does not respond to standard therapy, closely monitor the patient and discontinue Skyrizi until the infection is resolved.
- -Tuberculosis (TB): Screen patients for TB before starting Skyrizi 150 mg. Monitor for signs and symptoms of active TB during and after treatment. Do not administer Skyrizi to patients with active TB.
- -Vaccinations: Avoid live vaccines in patients receiving Risankizumab-rzaa. Immune-modulating drugs may increase the risk of infection from live vaccines. Ensure all age-appropriate vaccinations are completed according to current guidelines before starting therapy.
- -Severe Hypersensitivity Reactions: Severe reactions, including anaphylaxis, can occur with Skyrizi 75 mg or other dosages. If a serious hypersensitivity reaction occurs, discontinue the drug and initiate appropriate treatment immediately.
- -Overdose Management: In case of overdose, monitor the patient for signs and symptoms of adverse effects and provide appropriate symptomatic treatment promptly.
Documentation Availability
Documents required to import SKYRIZI to India?
SKYRIZI (Risankizumab-rzaa) Injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing SKYRIZI (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Skyrizi®?
The generic name for Skyrizi® is risankizumab-rzaa.
Who manufactures Skyrizi®?
Skyrizi® is produced by AbbVie Inc.
Is Skyrizi® FDA approved?
Yes, Skyrizi® received FDA approval on April 23, 2019.
What dosage and form is Skyrizi® available in?
Skyrizi® is available as an injection: 150 mg/mL in single-dose prefilled pens, and 150 mg/mL & 75 mg/0.83 mL in single-dose prefilled syringes for subcutaneous use.
What are the most common side effects of Skyrizi®?
For Plaque Psoriasis and Psoriatic Arthritis: common side effects include tinea infections, upper respiratory infections, injection site reactions, headache, and fatigue.
For Crohn’s Disease: common side effects during induction include upper respiratory infections, headache, and arthralgia. During maintenance, side effects include arthralgia, injection site reactions, abdominal pain, pyrexia, anemia, back pain, arthropathy, and urinary tract infection.
How much does Skyrizi® cost in India?
The cost of Skyrizi® 150 mg injection in India is reasonable. To purchase this interleukin-23 antagonist, you can reach out to Rx4u team.
What are the storage conditions for Skyrizi®?
Store Skyrizi® in a refrigerator at 2-8°C (36-46°F). Do not freeze or shake. Keep prefilled pens and syringes in their original cartons to protect them from light.
Is it safe to buy Skyrizi® online in India?
Yes, you can safely purchase Skyrizi® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
